fludarabine has been researched along with cyclin d1 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alomari, M; Best, OG; Christopherson, RI; Haynes, PA; Jenkins, Y; Kaufman, KL; Mactier, S; Mirzaei, M; Mulligan, SP; Pascovici, D | 1 |
Abuelgasim, KA; Al Atwi, N; Al Balwi, M; Almughairi, A; Alshieban, S; Alsubaie, M; Rehan, H | 1 |
1 review(s) available for fludarabine and cyclin d1
Article | Year |
---|---|
Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 12; Cyclin D1; Cyclophosphamide; Disease Progression; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Rituximab; Treatment Outcome; Trisomy; Vidarabine | 2018 |
1 other study(ies) available for fludarabine and cyclin d1
Article | Year |
---|---|
The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; BRCA1 Protein; Cell Line, Tumor; Chromatography, Liquid; Cyclin D1; DNA Damage; DNA Repair; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; NF-kappa B p52 Subunit; Nucleolin; Phosphoproteins; Protein Interaction Maps; Proteomics; Proto-Oncogene Proteins c-myc; RNA-Binding Proteins; Signal Transduction; Tandem Mass Spectrometry; Tumor Suppressor Protein p53; Vidarabine | 2015 |